World's leading pharma services company rated highest in overall
satisfaction
RESEARCH TRIANGLE PARK, N.C., April 10 /PRNewswire/ -- Quintiles
Transnational Corp. today announced that an independently conducted study
of clinical investigator sites across Europe placed Quintiles first in
overall satisfaction. Quintiles also rated first in several other
indicators of a clinical investigator's commitment to work with the world's
leading pharmaceutical services provider.
Eighty-four percent of sites indicated that they were satisfied or
extremely satisfied with their relationship with Quintiles.
The study, blinded and conducted by a third party, asked more than 300
European clinical investigators in 18 countries to rate their relationships
and experience with Clinical Research Organizations (CROs). Investigators
recruit patients and collect data for CROs and their pharmaceutical and
biotechnology sponsors in studies that test drugs for safety and efficacy.
Quintiles and eight other CROs were rated on 15 attributes by the
investigator sites, including overall satisfaction, relationship building
and allocation of resources for projects, including staff time.
"It is especially pleasing to see these results from all of our efforts
to build strong relationships with investigators," said Lindy Jones, Vice
President, Clinical Operations, Western Europe and Africa. "Because of our
hard work, it is clear the sites are willing to devote more of their
resources to projects they conduct with Quintiles than other CROs."
Clinical sites were asked to assign a percentage of resources -- such
as time spent on patient recruitment -- that they had used on clinical
studies with each CRO. Quintiles was allocated 38% of resources by the
sites, with the nearest competitor being assigned only 13%, according to
the survey. As for expected allocation of resources in the future, sites
plan to continue giving additional resources to Quintiles projects at about
a 3:1 ratio over other CROs.
"Allocation of resource is an important measure because it tells us
where sites are more willing to put their limited time and effort," said
Jones. "These results show that sites feel they get more return on their
investment by working with Quintiles."
The relationship measurement was based on the question, "Which provider
works hardest to develop a relationship with you/your site?" Quintiles was
named by 49% of respondents. The closest competitor was named by only 10%.
Janos Filakovsky, Vice President and Managing Director, Eastern Region
and Middle East, said, "Our continuing efforts to build strong
relationships ultimately lead to more efficient use of time and resources,
and that makes our customers happy. The end goal is more accurate
feasibility, faster recruitment and safer patient management in clinical
trials."
A third-party research company interviewed 308 investigators across
Europe from January to February 2008. Investigators rated only those CROs
with whom they had worked in the last 18 months. Respondents had an average
of 13 years of experience in conducting clinical research, and sites had
conducted an average of 11 studies over the last 18 months. For source
data, please refer to http://www.quintiles.com/results .
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
pharmaceutical, biotechnology and healthcare industries. With more than
20,000 employees and offices in more than 50 countries, it is focused on
providing customer-centric solutions that are the gold standard of the
industry. For more information, please visit the company's Web site at
http://www.quintiles.com.
SOURCE Quintiles Transnational Corp.
 back to top
Related links:
http://www.quintiles.com
http://www.quintiles.com/results
CONTACT:
Dick Jones, Media Relations, +1-919-998-2091,
media.info@quintiles.com, or Greg Connors, Investor Relations,
+1-919-998-2000, invest@quintiles.com
|
